$CRMD
CorMedix Inc. Stock $crmd

$crmd Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022046617 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$6.817K	$21.25K	$7.640K
YoY Change	-82.1%	159.47%	-91.51%
Cost Of Revenue	$1.469K	$332.00	$1.530K
YoY Change	-94.16%	-97.7%	-97.45%
Gross Profit	$5.348K	$20.92K	$6.110K
YoY Change	-58.61%	-435.54%	-79.63%
Gross Profit Margin	78.45%	98.44%	79.97%
Selling, General & Admin	$4.628M	$5.052M	$4.751M
YoY Change	20.63%	50.54%	3.28%
% of Gross Profit	86537.28%	24147.48%	77755.81%
Research & Development	$2.339M	$3.209M	$2.288M
YoY Change	-50.66%	27.35%	-13.35%
% of Gross Profit	43740.99%	15340.91%	37440.1%
Depreciation & Amortization	$21.28K	$20.57K	$20.25K
YoY Change	21.18%	44.05%	102.5%
% of Gross Profit	397.91%	98.32%	331.42%
Operating Expenses	$6.967M	$8.261M	$7.038M
YoY Change	-18.78%	40.6%	-2.78%
Operating Profit	-$6.962M	-$8.240M	-$7.032M
YoY Change	-18.72%	40.09%	-2.46%
Interest Expense	$8.776K	$3.585K	-$1.830K
YoY Change	-297.21%		-81.7%
% of Operating Profit
Other Income/Expense, Net	$108.2K	$49.99K	-$1.833K
YoY Change	-2533.39%	-5697.87%
Pretax Income	-$6.854M	-$8.190M	-$7.034M
YoY Change	-20.02%	39.22%	-2.57%
Income Tax	$0.00	-$585.6K
% Of Pretax Income
Net Earnings	-$6.854M	-$7.605M	-$7.034M
YoY Change	-20.02%	64.15%	-2.57%
Net Earnings / Revenue	-100538.67%	-35782.43%	-92070.55%
Basic Earnings Per Share	-$0.17	-$0.19	-$0.18
Diluted Earnings Per Share	-$0.17	-$0.19	-$183.9K
COMMON SHARES
Basic Shares Outstanding	41.11M shares	39.76M shares	38.25M shares
Diluted Shares Outstanding	41.18M shares	39.76M shares	38.25M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$59.00M	$64.62M	$61.69M
YoY Change	-18.02%	-17.42%	-24.0%
Cash & Equivalents	$43.25M	$48.93M	$45.39M
Short-Term Investments	$15.75M	$15.69M	$16.30M
Other Short-Term Assets	$663.6K	$734.8K	$810.2K
YoY Change	-31.75%	-46.06%	-53.97%
Inventory	$269.00	$1.720K	$2.610K
Prepaid Expenses	$19.12K	$28.45K
Receivables	$0.00	$0.00	$2.980K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$59.66M	$65.36M	$62.50M
YoY Change	-18.26%	-17.98%	-24.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.503M	$1.448M	$2.328M
YoY Change	-34.53%	36.09%	111.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$102.3K	$102.3K	$102.3K
YoY Change	0.01%	0.01%	2.31%
Total Long-Term Assets	$2.413M	$2.389M	$2.430M
YoY Change	0.59%	104.78%	102.54%
TOTAL ASSETS
Total Short-Term Assets	$59.66M	$65.36M	$62.50M
Total Long-Term Assets	$2.413M	$2.389M	$2.430M
Total Assets	$62.08M	$67.75M	$64.93M
YoY Change	-17.66%	-16.21%	-22.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.767M	$2.496M	$1.740M
YoY Change	59.67%	164.6%	16.0%
Accrued Expenses	$3.163M	$2.649M	$2.554M
YoY Change	-22.92%	21.5%	64.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.062M	$5.272M	$4.294M
YoY Change	-2.86%	68.8%	40.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$703.0K	$736.9K	$770.0K
YoY Change	-15.71%	-14.74%	-13.48%
Total Long-Term Liabilities	$703.0K	$736.9K	$770.0K
YoY Change	-15.71%	-14.74%	-13.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.062M	$5.272M	$4.294M
Total Long-Term Liabilities	$703.0K	$736.9K	$770.0K
Total Liabilities	$5.765M	$6.009M	$5.064M
YoY Change	-4.64%	50.69%	28.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$267.2M	-$260.3M
YoY Change
Common Stock	$41.21K	$41.11K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$56.31M	$61.74M	$59.87M
YoY Change
Total Liabilities & Shareholders Equity	$62.08M	$67.75M	$64.93M
YoY Change	-17.66%	-16.21%	-22.94%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$6.854M	-$7.605M	-$7.034M
YoY Change	-20.02%	64.15%	-2.57%
Depreciation, Depletion And Amortization	$21.28K	$20.57K	$20.25K
YoY Change	21.18%	44.05%	102.5%
Cash From Operating Activities	-$5.995M	-$5.462M	-$6.744M
YoY Change	8.94%	76.63%	0.81%
INVESTING ACTIVITIES
Capital Expenditures	-$76.42K	-$9.870K	-$4.320K
YoY Change	-90.18%	13.45%	-56.8%
Acquisitions
YoY Change
Other Investing Activities	-$37.87K	$604.3K	-$4.183M
YoY Change	-92.33%	-393.93%	720.26%
Cash From Investing Activities	-$114.3K	$594.4K	-$4.188M
YoY Change	-91.01%	-390.98%	690.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	437.3K	8.411M	3.004M
YoY Change		4637.34%	-92.77%
NET CHANGE
Cash From Operating Activities	-5.995M	-5.462M	-6.744M
Cash From Investing Activities	-114.3K	594.4K	-4.188M
Cash From Financing Activities	437.3K	8.411M	3.004M
Net Change In Cash	-5.672M	3.543M	-7.928M
YoY Change	-16.27%	-213.61%	-123.07%
FREE CASH FLOW
Cash From Operating Activities	-$5.995M	-$5.462M	-$6.744M
Capital Expenditures	-$76.42K	-$9.870K	-$4.320K
Free Cash Flow	-$5.919M	-$5.452M	-$6.740M
YoY Change	25.25%	76.81%	0.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34673
	dei	Entity Registrant Name EntityRegistrantName	CORMEDIX INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5894890
	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Connell Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 4200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berkeley Heights
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07922
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	517-9500
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	CRMD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41111277	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48929895	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53317405	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	121214	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	131567	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	15692548	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	12149003	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	45368	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1720	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3008	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	28451	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	51993	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	585141	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	770485	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	65358969	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	66468829	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1448305	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1474937	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102308	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102305	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	838121	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899505	usd
CY2022Q2	us-gaap	Assets Assets	67747703	usd
CY2021Q4	us-gaap	Assets Assets	68945576	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2496074	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2209552	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2648626	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3014156	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127408	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121368	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5272108	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5345076	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	736855	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	802433	usd
CY2022Q2	us-gaap	Liabilities Liabilities	6008963	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6147509	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41106777	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41106777	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38086437	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38086437	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	41107	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	38086	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	39519	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	87130	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	321956046	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	308331750	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-260298114	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245659081	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	61738740	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62798067	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67747703	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68945576	usd
CY2022Q2	us-gaap	Revenues Revenues	21253	usd
CY2021Q2	us-gaap	Revenues Revenues	8191	usd
	us-gaap	Revenues Revenues	28889	usd
	us-gaap	Revenues Revenues	96451	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	332	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	14426	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1859	usd
	us-gaap	Cost Of Revenue CostOfRevenue	75765	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	20921	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	-6235	usd
	us-gaap	Gross Profit GrossProfit	27030	usd
	us-gaap	Gross Profit GrossProfit	20686	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3209471	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2520203	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5497058	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5156535	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5051895	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3355790	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9802778	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7956896	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8261366	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	5875993	usd
	us-gaap	Operating Expenses OperatingExpenses	15299836	usd
	us-gaap	Operating Expenses OperatingExpenses	13113431	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8240445	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5882228	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15272806	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13092745	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	35342	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34673
	dei	Entity Registrant Name EntityRegistrantName	CORMEDIX INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5894890
	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Connell Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 4200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berkeley Heights
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07922
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	517-9500
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	CRMD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41111277	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48929895	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53317405	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	121214	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	131567	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3340	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	49094	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7014	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	18232	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4233	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	8026	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9144	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	3585	usd
	us-gaap	Interest Expense InterestExpense	8964	usd
	us-gaap	Interest Expense InterestExpense	5184	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	49989	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-893	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48156	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7314	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8190456	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5883121	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15224650	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13100059	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-585617	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1250186	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-585617	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1250186	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-7604839	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4632935	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14639033	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11849873	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	1316	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	662	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	35488	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	315	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9086	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1017	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12123	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2510	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-10402	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	355	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-47611	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2825	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7615241	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4632580	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14686644	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11852698	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39761754	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38083842	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39008590	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37211233	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	59869179	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8411156	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	1073646	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-10402	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-7604839	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	61738740	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62798067	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11415372	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	2211945	usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-47611	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14639033	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	61738740	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	80315067	usd
CY2021Q2	crmd	Stock Issued In Connection With Warrants Exercised Cash StockIssuedInConnectionWithWarrantsExercisedCash	39957	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	137035	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	1010066	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	355	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4632935	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	76869545	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	44223012	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	41455630	usd
	crmd	Stock Issued In Connection With Warrants Exercised Cash StockIssuedInConnectionWithWarrantsExercisedCash	164886	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	137035	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	2741680	usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-2825	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11849873	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	76869545	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14639033	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11849873	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2211945	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2741680	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	61383	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	56350	usd
	us-gaap	Depreciation Depreciation	40819	usd
	us-gaap	Depreciation Depreciation	24277	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-43738	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-72	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1288	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-75737	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-208535	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-265019	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	287011	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-184681	usd
	crmd	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	362604	usd
	crmd	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	857924	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-59539	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-52983	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12206457	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9782326	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	14279033	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	7595280	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	10700000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	6879685	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14187	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18698	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3593220	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-734293	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11415372	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	41455630	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	164886	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	137035	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11415372	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41757551	usd
	crmd	Foreign Exchange Effect On Cash ForeignExchangeEffectOnCash	13555	usd
	crmd	Foreign Exchange Effect On Cash ForeignExchangeEffectOnCash	4500	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4397860	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31236432	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53551277	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42096783	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49153417	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73333215	usd
	us-gaap	Interest Paid Net InterestPaidNet	8964	usd
	us-gaap	Interest Paid Net InterestPaidNet	5184	usd
	crmd	Conversion Of Series G Preferred Stock To Common Stock ConversionOfSeriesGPreferredStockToCommonStock	10	usd
	crmd	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	50	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-35488	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-315	usd
	crmd	Organization And Business Description OrganizationAndBusinessDescription	The Company has in-licensed the worldwide rights to develop and commercialize DefenCath/Neutrolin®, which is a novel anti-infective solution (a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL) intended for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters, or CVCs, in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. Infection and thrombosis represent key complications among hemodialysis, total parenteral nutrition and cancer patients with CVCs. These complications can lead to treatment delays and increased costs to the healthcare system when they occur due to hospitalizations, need for intravenous, or IV, antibiotic treatment, long-term anticoagulation therapy, removal/replacement of the CVC, related treatment costs and increased mortality. The name DefenCath is the U.S. proprietary name conditionally approved by the U.S. Food and Drug Administration, or FDA, while the name Neutrolin is currently used in the European Union, or EU, and other territories where the Company has received CE-Mark approval for the commercial distribution of Neutrolin as a catheter lock solution, or CLS, regulated as a medical device.
	crmd	Defencath Relative To The Active Control Description DefencathRelativeToTheActiveControlDescription	As previously agreed with the FDA, an interim efficacy analysis was performed when the first 28 potential CRBSI cases were identified in our LOCK-IT-100 study that occurred through early December 2017. Based on these first 28 cases, there was a highly statistically significant 72% reduction in CRBSI by DefenCath relative to the active control of heparin (p=0.0034). Because the pre-specified level of statistical significance was reached for the primary endpoint and efficacy had been demonstrated with no safety concerns, the LOCK-IT-100 study was terminated early. The study continued enrolling and treating subjects until study termination, and the final analysis was based on a total of 795 subjects. In a total of 41 cases, there was a 71% reduction in CRBSI by DefenCath relative to heparin, which was highly statistically significant (p=0.0006), with a good safety profile.
	crmd	Pediatric Research Equity Act Description PediatricResearchEquityActDescription	Pediatric studies for an approved product conducted under PREA may qualify for pediatric exclusivity, which if granted would provide an additional six months of marketing exclusivity. DefenCath would then have the potential to receive a total marketing exclusivity period of 10.5 years, including exclusivity pursuant to NCE and QIDP.
CY2022Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	-260300000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7600000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4600000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14600000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	11800000	usd
	crmd	Available Under The Atm Program AvailableUnderTheATMProgram	38200000	usd
	crmd	Available Under The Shelf Registration AvailableUnderTheShelfRegistration	150000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications were made to the prior year’s amounts to conform to the 2022 presentation. Non-cash lease expense, as presented on the Company’s condensed consolidated statement of cash flows for the six months ended June 30, 2021, is now presented as change in right-of-use assets and change in operating lease liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48929895	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53317405	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	223522	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	233872	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	49153417	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	53551277	usd
	us-gaap	Deferred Compensation Arrangement With Individual Maximum Contractual Term1 DeferredCompensationArrangementWithIndividualMaximumContractualTerm1	P1Y
CY2022Q2	crmd	Amortized Cost AmortizedCost	22683996	usd
CY2022Q2	crmd	Gross Unrealized Losses GrossUnrealizedLosses	41145	usd
CY2022Q2	crmd	Fair Value FairValue	22642851	usd
CY2021Q4	crmd	Amortized Cost AmortizedCost	22617515	usd
CY2021Q4	crmd	Gross Unrealized Losses GrossUnrealizedLosses	5751	usd
CY2021Q4	crmd	Gross Unrealized Gains GrossUnrealizedGains	93	usd
CY2021Q4	crmd	Fair Value FairValue	22611857	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22642851	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22611857	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	9000	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	1000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	38086	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	39519	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	87130	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	321956046	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	15692548	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	12149003	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	45368	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1720	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3008	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	28451	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	51993	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	585141	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	770485	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	65358969	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	66468829	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1448305	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1474937	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102308	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102305	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	838121	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899505	usd
CY2022Q2	us-gaap	Assets Assets	67747703	usd
CY2021Q4	us-gaap	Assets Assets	68945576	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2496074	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2209552	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2648626	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3014156	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127408	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121368	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5272108	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5345076	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	736855	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	802433	usd
CY2022Q2	us-gaap	Liabilities Liabilities	6008963	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6147509	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	121000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	132000	usd
CY2022Q2	crmd	Longterm Restricted Cash LongtermRestrictedCash	102000	usd
	crmd	Prepaid Expenses Policy Textblock PrepaidExpensesPolicyTextblock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prepaid Research and Development and Other Prepaid Expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, manufacturing, preclinical development and insurance policies. These advanced payments are amortized to expense either as services are performed or over the relevant service period using the straight-line method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1720	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3008	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41106777	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41106777	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38086437	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38086437	shares
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	589885	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	311408	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1787260	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2508398	usd
CY2022Q2	crmd	Accrued Manufacturing Development AccruedManufacturingDevelopment	186539	usd
CY2021Q4	crmd	Accrued Manufacturing Development AccruedManufacturingDevelopment	99614	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	84942	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94736	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2648626	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3014156	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10146140	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9271132	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	41107	usd
CY2022Q2	us-gaap	Revenues Revenues	21253	usd
CY2021Q2	us-gaap	Revenues Revenues	8191	usd
	us-gaap	Revenues Revenues	28889	usd
	us-gaap	Revenues Revenues	96451	usd
	crmd	Net Proceeds NetProceeds	11415000	usd
	crmd	Shares Of Common Stock SharesOfCommonStock	656069	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
	crmd	Preferred Shares Was Converted Description PreferredSharesWasConvertedDescription	During the six months ended June 30, 2021, 50,000 Series C-3 preferred shares was converted into 100,000 shares of the Company’s common stock by an unrelated party and 10,001 Series G preferred shares was converted into 556,069 shares of the Company’s common stock by a related party.
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0117	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.82
CY2022Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	207469	shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.38
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y7M6D
CY2020	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	30000	usd
	crmd	Cash Reimburse CashReimburse	41000	usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	121000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	308331750	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-260298114	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245659081	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	61738740	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62798067	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67747703	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68945576	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	332	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	14426	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1859	usd
	us-gaap	Cost Of Revenue CostOfRevenue	75765	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	20921	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	-6235	usd
	us-gaap	Gross Profit GrossProfit	27030	usd
	us-gaap	Gross Profit GrossProfit	20686	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3209471	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2520203	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5497058	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5156535	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5051895	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3355790	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9802778	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7956896	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8261366	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	5875993	usd
	us-gaap	Operating Expenses OperatingExpenses	15299836	usd
	us-gaap	Operating Expenses OperatingExpenses	13113431	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8240445	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5882228	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15272806	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13092745	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	35342	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3340	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	49094	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7014	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	18232	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4233	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	8026	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9144	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	3585	usd
	us-gaap	Interest Expense InterestExpense	8964	usd
CY2008Q4	crmd	Amount Of Initial Licensing Fee AmountOfInitialLicensingFee	325000	usd
CY2008Q4	crmd	Shares Of Equity Of Common Stock SharesOfEquityOfCommonStock	7996	shares
	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	29109	shares
CY2014	crmd	Number Of Shares Released In Escrow NumberOfSharesReleasedInEscrow	7277	shares
	crmd	Number Of Share Held In Escrow Of Common Stock NumberOfShareHeldInEscrowOfCommonStock	21832	shares
	crmd	Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones	3000000	usd
	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2500000	usd
	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2500000	usd
	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The Company entered into a seven-year operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922. The lease agreement, with a monthly average cost of approximately $17,000 commenced in September 2020.
	crmd	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
CY2022Q2	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	104000	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	105000	usd
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	the Company has a total operating lease liability of $864,000, of which $127,000 was classified as operating lease liabilities, short-term and $737,000 was classified as operating lease liabilities, net of current portion, on the condensed consolidated balance sheet. At December 31, 2021, the Company’s total operating lease liability was $924,000 of which $122,000 was classified as operating lease liabilities, short-term and $802,000 was classified as operating lease liabilities, net of current portion, on the condensed consolidated balance sheet. Operating ROU assets as of June 30, 2022 and December 31, 2021 are $838,000 and $900,000, respectively.
CY2022Q2	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	50000	usd
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	100000	usd
CY2021Q2	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	45000	usd
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	97000	usd
	crmd	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P5Y3M18D
	crmd	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P6Y3M18D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due Year Two LesseeOperatingLeaseLiabilityPaymentDueYearTwo	100000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due Year Three LesseeOperatingLeaseLiabilityPaymentDueYearThree	202000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due Year Four LesseeOperatingLeaseLiabilityPaymentDueYearFour	205000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due Year Five LesseeOperatingLeaseLiabilityPaymentDueYearFive	208000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due After Year Five LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive	380000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due LesseeOperatingLeaseLiabilityPaymentDue	1095000	usd
CY2022Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	231000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	864000	usd
	us-gaap	Interest Expense InterestExpense	5184	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	49989	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-893	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48156	usd
	crmd	Accounts Receivable From Customers Percentage AccountsReceivableFromCustomersPercentage	0.10	pure
CY2022Q2	crmd	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
	crmd	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
CY2021Q2	crmd	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	crmd	Conversion Of Series G Preferred Stock To Common Stock ConversionOfSeriesGPreferredStockToCommonStock		usd
	crmd	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
CY2022Q2	crmd	Gross Unrealized Gains GrossUnrealizedGains		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001410098
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7314	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8190456	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5883121	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15224650	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13100059	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-585617	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1250186	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-585617	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1250186	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-7604839	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4632935	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14639033	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11849873	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	1316	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	662	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	35488	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	315	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9086	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1017	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12123	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2510	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-10402	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	355	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-47611	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2825	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7615241	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4632580	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14686644	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11852698	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39761754	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38083842	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39008590	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37211233	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	59869179	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8411156	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	1073646	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-10402	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-7604839	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	61738740	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62798067	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11415372	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	2211945	usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-47611	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14639033	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	61738740	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	80315067	usd
CY2021Q2	crmd	Stock Issued In Connection With Warrants Exercised Cash StockIssuedInConnectionWithWarrantsExercisedCash	39957	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	137035	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	1010066	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	355	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4632935	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	76869545	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	44223012	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	41455630	usd
	crmd	Stock Issued In Connection With Warrants Exercised Cash StockIssuedInConnectionWithWarrantsExercisedCash	164886	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	137035	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	2741680	usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-2825	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11849873	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	76869545	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14639033	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11849873	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2211945	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2741680	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	61383	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	56350	usd
	us-gaap	Depreciation Depreciation	40819	usd
	us-gaap	Depreciation Depreciation	24277	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-43738	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-72	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1288	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-75737	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-208535	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-265019	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	287011	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-184681	usd
	crmd	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	362604	usd
	crmd	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	857924	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-59539	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-52983	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12206457	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9782326	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	14279033	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	7595280	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	10700000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	6879685	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14187	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18698	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3593220	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-734293	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11415372	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	41455630	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	164886	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	137035	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11415372	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41757551	usd
	crmd	Foreign Exchange Effect On Cash ForeignExchangeEffectOnCash	13555	usd
	crmd	Foreign Exchange Effect On Cash ForeignExchangeEffectOnCash	4500	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4397860	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31236432	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53551277	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42096783	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49153417	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73333215	usd
	us-gaap	Interest Paid Net InterestPaidNet	8964	usd
	us-gaap	Interest Paid Net InterestPaidNet	5184	usd
	crmd	Conversion Of Series G Preferred Stock To Common Stock ConversionOfSeriesGPreferredStockToCommonStock	10	usd
	crmd	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	50	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-35488	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-315	usd
	crmd	Organization And Business Description OrganizationAndBusinessDescription	The Company has in-licensed the worldwide rights to develop and commercialize DefenCath/Neutrolin®, which is a novel anti-infective solution (a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL) intended for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters, or CVCs, in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. Infection and thrombosis represent key complications among hemodialysis, total parenteral nutrition and cancer patients with CVCs. These complications can lead to treatment delays and increased costs to the healthcare system when they occur due to hospitalizations, need for intravenous, or IV, antibiotic treatment, long-term anticoagulation therapy, removal/replacement of the CVC, related treatment costs and increased mortality. The name DefenCath is the U.S. proprietary name conditionally approved by the U.S. Food and Drug Administration, or FDA, while the name Neutrolin is currently used in the European Union, or EU, and other territories where the Company has received CE-Mark approval for the commercial distribution of Neutrolin as a catheter lock solution, or CLS, regulated as a medical device.
	crmd	Defencath Relative To The Active Control Description DefencathRelativeToTheActiveControlDescription	As previously agreed with the FDA, an interim efficacy analysis was performed when the first 28 potential CRBSI cases were identified in our LOCK-IT-100 study that occurred through early December 2017. Based on these first 28 cases, there was a highly statistically significant 72% reduction in CRBSI by DefenCath relative to the active control of heparin (p=0.0034). Because the pre-specified level of statistical significance was reached for the primary endpoint and efficacy had been demonstrated with no safety concerns, the LOCK-IT-100 study was terminated early. The study continued enrolling and treating subjects until study termination, and the final analysis was based on a total of 795 subjects. In a total of 41 cases, there was a 71% reduction in CRBSI by DefenCath relative to heparin, which was highly statistically significant (p=0.0006), with a good safety profile.
	crmd	Pediatric Research Equity Act Description PediatricResearchEquityActDescription	Pediatric studies for an approved product conducted under PREA may qualify for pediatric exclusivity, which if granted would provide an additional six months of marketing exclusivity. DefenCath would then have the potential to receive a total marketing exclusivity period of 10.5 years, including exclusivity pursuant to NCE and QIDP.
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	233872	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	49153417	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	53551277	usd
CY2022Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	-260300000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7600000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4600000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14600000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	11800000	usd
	crmd	Available Under The Atm Program AvailableUnderTheATMProgram	38200000	usd
	crmd	Available Under The Shelf Registration AvailableUnderTheShelfRegistration	150000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications were made to the prior year’s amounts to conform to the 2022 presentation. Non-cash lease expense, as presented on the Company’s condensed consolidated statement of cash flows for the six months ended June 30, 2021, is now presented as change in right-of-use assets and change in operating lease liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48929895	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53317405	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	223522	usd
	us-gaap	Deferred Compensation Arrangement With Individual Maximum Contractual Term1 DeferredCompensationArrangementWithIndividualMaximumContractualTerm1	P1Y
CY2022Q2	crmd	Amortized Cost AmortizedCost	22683996	usd
CY2022Q2	crmd	Gross Unrealized Losses GrossUnrealizedLosses	41145	usd
CY2022Q2	crmd	Fair Value FairValue	22642851	usd
CY2021Q4	crmd	Amortized Cost AmortizedCost	22617515	usd
CY2021Q4	crmd	Gross Unrealized Losses GrossUnrealizedLosses	5751	usd
CY2021Q4	crmd	Gross Unrealized Gains GrossUnrealizedGains	93	usd
CY2021Q4	crmd	Fair Value FairValue	22611857	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22642851	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22611857	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	9000	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	1000	usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.38
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y7M6D
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	121000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	132000	usd
CY2022Q2	crmd	Longterm Restricted Cash LongtermRestrictedCash	102000	usd
	crmd	Prepaid Expenses Policy Textblock PrepaidExpensesPolicyTextblock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prepaid Research and Development and Other Prepaid Expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, manufacturing, preclinical development and insurance policies. These advanced payments are amortized to expense either as services are performed or over the relevant service period using the straight-line method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	crmd	Net Proceeds NetProceeds	11415000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1720	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3008	usd
CY2020	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	30000	usd
	crmd	Cash Reimburse CashReimburse	41000	usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	121000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	589885	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	311408	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1787260	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2508398	usd
CY2022Q2	crmd	Accrued Manufacturing Development AccruedManufacturingDevelopment	186539	usd
CY2021Q4	crmd	Accrued Manufacturing Development AccruedManufacturingDevelopment	99614	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	84942	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94736	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2648626	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3014156	usd
	crmd	Shares Of Common Stock SharesOfCommonStock	656069	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10146140	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9271132	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
	crmd	Preferred Shares Was Converted Description PreferredSharesWasConvertedDescription	During the six months ended June 30, 2021, 50,000 Series C-3 preferred shares was converted into 100,000 shares of the Company’s common stock by an unrelated party and 10,001 Series G preferred shares was converted into 556,069 shares of the Company’s common stock by a related party.
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0117	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.82
CY2022Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	207469	shares
CY2008Q4	crmd	Amount Of Initial Licensing Fee AmountOfInitialLicensingFee	325000	usd
CY2008Q4	crmd	Shares Of Equity Of Common Stock SharesOfEquityOfCommonStock	7996	shares
	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	29109	shares
CY2014	crmd	Number Of Shares Released In Escrow NumberOfSharesReleasedInEscrow	7277	shares
	crmd	Number Of Share Held In Escrow Of Common Stock NumberOfShareHeldInEscrowOfCommonStock	21832	shares
	crmd	Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones	3000000	usd
	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2500000	usd
	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2500000	usd
	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The Company entered into a seven-year operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922. The lease agreement, with a monthly average cost of approximately $17,000 commenced in September 2020.
CY2022Q2	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	104000	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	105000	usd
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	the Company has a total operating lease liability of $864,000, of which $127,000 was classified as operating lease liabilities, short-term and $737,000 was classified as operating lease liabilities, net of current portion, on the condensed consolidated balance sheet. At December 31, 2021, the Company’s total operating lease liability was $924,000 of which $122,000 was classified as operating lease liabilities, short-term and $802,000 was classified as operating lease liabilities, net of current portion, on the condensed consolidated balance sheet. Operating ROU assets as of June 30, 2022 and December 31, 2021 are $838,000 and $900,000, respectively.
CY2022Q2	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	50000	usd
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	100000	usd
CY2021Q2	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	45000	usd
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	97000	usd
	crmd	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P5Y3M18D
	crmd	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P6Y3M18D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due Year Two LesseeOperatingLeaseLiabilityPaymentDueYearTwo	100000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due Year Three LesseeOperatingLeaseLiabilityPaymentDueYearThree	202000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due Year Four LesseeOperatingLeaseLiabilityPaymentDueYearFour	205000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due Year Five LesseeOperatingLeaseLiabilityPaymentDueYearFive	208000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due After Year Five LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive	380000	usd
CY2022Q2	crmd	Lessee Operating Lease Liability Payment Due LesseeOperatingLeaseLiabilityPaymentDue	1095000	usd
CY2022Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	231000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	864000	usd
	crmd	Accounts Receivable From Customers Percentage AccountsReceivableFromCustomersPercentage	0.10	pure
CY2022Q2	crmd	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
	crmd	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
CY2021Q2	crmd	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
	crmd	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001410098

Files In Submission

Name	View Source	Status
0001213900-22-046617-index-headers.html	Edgar Link	pending
0001213900-22-046617-index.html	Edgar Link	pending
0001213900-22-046617.txt	Edgar Link	pending
0001213900-22-046617-xbrl.zip	Edgar Link	pending
crmd-20220630.xsd	Edgar Link	pending
f10q0622ex31-1_cormedixinc.htm	Edgar Link	pending
f10q0622ex31-2_cormedixinc.htm	Edgar Link	pending
f10q0622ex32-1_cormedixinc.htm	Edgar Link	pending
f10q0622ex32-2_cormedixinc.htm	Edgar Link	pending
f10q0622_cormedix.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
crmd-20220630_lab.xml	Edgar Link	unprocessable
crmd-20220630_cal.xml	Edgar Link	unprocessable
crmd-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
crmd-20220630_pre.xml	Edgar Link	unprocessable
f10q0622_cormedix_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRMD
CorMedix Inc. Stock $crmd

2022 Q3 Form 10-Q Financial Statement

#000121390022046617 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD CorMedix Inc. Stock $crmd

2022 Q3 Form 10-Q Financial Statement

#000121390022046617 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD
CorMedix Inc. Stock $crmd